INOTREM
23.6.2021 08:02:27 CEST | Business Wire | Press release
Inotrem, an advanced clinical stage biotech company specialized in immunotherapies for acute and chronic inflammatory syndromes, announced today that it has filed a patent to protect a new therapeutic modality against TREM-1, a monoclonal antibody.
The filing of this monoclonal antibody patent is a significant milestone for Inotrem’s strategic development as it represents the company’s second asset, next to nangibotide, and a further diversification of its drug portfolio. Moreover, by modulating the activity of the TREM-1 pathway over extended periods of time, this therapeutic modality offers a new and promising alternative for the treatment of chronic inflammatory diseases.
TREM-1 is an immunoreceptor initially discovered for its role in the pathophysiology of acute inflammatory syndromes and in particular septic shock. Since its inception in 2013, Inotrem has introduced the therapeutic peptide nangibotide into the clinics for acute inflammatory syndromes secondary to severe infections. Two Phase IIB clinical trials are currently ongoing in septic shock and COVID-19 patients. Since its discovery in 2000, an increasing number of research work indicated the implication of the therapeutic target TREM-1 in not only acute inflammatory diseases but also in the development of chronic inflammation. Pioneering these approaches, Inotrem initiated in 2019 a proprietary research and discovery program to identify a new modality against TREM-1 in the form of a therapeutic monoclonal antibody, with pharmacological properties suitable for the management of chronic indications.
“Inotrem’s research team’s exceptional commitment is at the core of today’s success. Adding a monoclonal antibody to our therapeutic modalities targeting the TREM-1 pathway now allows us to expand our development efforts beyond the current acute indications to also address chronic inflammatory syndromes with a high unmet medical need,” said Marc Derive, co-founder and Chief Scientific Officer of Inotrem.
“Today’s announcement constitutes a key advancement for Inotrem. This new patent application demonstrates the company’s ability to deploy its vision and strategy. Through its proprietary technology platform addressing inflammatory diseases, it has the potential to develop treatments in a wide number of inflammatory indications, both acute and now chronic, for which there are today no or limited specific treatment. We are looking forward to the clinical development progress of this new asset, with preclinical development slated to start later this year,” said Jean-Jacques Garaud, Executive Vice-President, Head of Scientific and Medical Affairs and Inotrem’s co-founder.
Chronic inflammatory diseases are inflammatory-driven diseases of the digestive system, joints, skin, respiratory system, kidneys, and various other organs. Most of them have no cure, and new biologics have recently reached the market to target inflammation. But there are still a high number of non-responders to these innovative drugs, and therefore a very significant unmet medical need.
About Inotrem
Inotrem S.A. is an advanced clinical stage biotech company specialized in immunotherapy for inflammatory syndromes. The company has developed a new concept of immunomodulation that targets the TREM-1 pathway to control unbalanced inflammatory responses. Through its proprietary technology platform, Inotrem has developed the first-in-class TREM-1 inhibitor, nangibotide, with potential applications in a number of therapeutic indications such as septic shock and COVID-19. In parallel, Inotrem has launched a program to develop new therapeutic modalities targeting chronic inflammatory diseases. The company was founded in 2013 by Dr. Jean-Jacques Garaud, a former head of research and early development at the Roche Group, Prof. Sébastien Gibot and Dr. Marc Derive. Inotrem is supported by leading European and North American investors. For more information please visit: www.inotrem.com
About TREM-1 pathway
TREM-1 pathway is an amplification loop of the immune response that triggers an exuberant and hyperactivated immune state which is known to play a crucial role in the pathophysiology of septic shock and acute myocardial infarction.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210622005982/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Samsung Bioepis Enters into Partnership Agreement with Sandoz for Up to Five Next-Generation Biosimilar Candidates18.3.2026 08:30:00 CET | Press release
The agreement covers up to five assets, including SB36, a biosimilar candidate referencing Entyvio (vedolizumab), for collaboration of development and commercialization in global markets excluding China, Hong Kong, Taiwan, Macau, and Republic of KoreaSamsung Bioepis continues to pave the way for access to life-changing medicines by advancing a biosimilar pipeline across immunology and oncology Samsung Bioepis Co., Ltd. announced today that the company has entered into a global license, development and commercialization agreement (DCA) with Sandoz for up to five biosimilar candidates under development by Samsung Bioepis, including SB36, a biosimilar candidate referencing Entyvio1 (vedolizumab). The other terms of the agreement remain confidential. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260318826412/en/ Samsung Bioepis office in Songdo, Incheon, Republic of Korea Under the terms of the agreement, Samsung Bioepis will b
Epassi Appoints Three Senior Leaders to Accelerate European Growth18.3.2026 08:00:00 CET | Press release
Epassi Group, a leading European multi-benefits technology platform, today announced the appointments of Phil Jones as Chief Revenue Officer (CRO), Ross Seychell as Chief People Officer (CPeO), and Cho Hwang as Chief Technology Officer (CTO), strengthening its leadership team as the company enters its next phase of expansion. Cho Hwang joined Epassi on December 1, 2025. He brings extensive global technology leadership experience from companies including HelloFresh, Coupang, and Nordstrom. At Epassi, Cho leads the company’s technology strategy and engineering organisation as the platform continues to scale across Europe. His experience will support Epassi’s ambition to further expand its multi-benefits ecosystem for employers, employees, and partners. Phil Jones joined Epassi on March 2. He brings extensive experience across HR technology and the full Human Capital Management lifecycle, having held senior leadership roles across Sales, Revenue Operations, and Customer Success at global
AiDEN Are Collaborating With Volvo Group Through the Innovation Hub CampX in a Proof-of-Value Project Solving Real Customer Needs18.3.2026 05:00:00 CET | Press release
In December 2024, a new regulatory requirement was introduced in Poland related to SENT (System for Electronic Transport Supervision) for tracking high-risk goods transported within the country. In regard to this, a project to validate one of AiDEN's services/products within the platform was initiated. This was done in a project with Volvo Trucks through CampX, Volvo Group’s global innovation arena for technology and business transformation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260317838896/en/ AiDEN’s SENT GEO compliance service displayed within a Volvo truck’s in-vehicle infotainment system, enabling automated geolocation reporting for Poland’s System for Electronic Transport Supervision (SENT). Developed through a collaboration between AiDEN Automotive and Volvo Group’s CampX innovation hub, the integrated solution allows fleets to meet SENT requirements without external GPS hardware or aftermarket installations
LTM Named NVIDIA Partner Network ‘Rising Star Consulting Partner of the Year’ at NVIDIA GTC 202618.3.2026 03:30:00 CET | Press release
LTM, the Business Creativity partner to the world’s largest enterprises, has been recognized as the NVIDIA Partner Network (NPN) ‘Rising Star Consulting Partner of the Year’ at NVIDIA GTC 2026. The award recognizes LTM’s strong collaboration with NVIDIA and its growing impact in helping enterprises move from AI experimentation to scalable, enterprise-ready adoption. The NVIDIA Partner Network (NPN) brings together a global ecosystem of technology and consulting partners working closely with NVIDIA to deliver advanced AI solutions. Being an NPN partner is about collaborating deeply with NVIDIA to help clients transition from AI pilots to enterprise-scale deployments combining NVIDIA’s advanced AI technologies with LTM’s industry and domain expertise to drive real-world outcomes. The Rising Star Consulting Partner of the Year award highlights LTM’s momentum in delivering AI solutions that are production-grade, secure, and designed for enterprise scale. This NPN award is a significant rec
SES Successfully Prices €650 million of SPACE Hybrid Securities17.3.2026 23:00:00 CET | Press release
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO OR TO ANY PERSON LOCATED OR RESIDENT IN, OR AT ANY ADDRESS IN, THE UNITED STATES OF AMERICA, ITS TERRITORIES AND POSSESSIONS (INCLUDING PUERTO RICO, THE U.S. VIRGIN ISLANDS, GUAM, AMERICAN SAMOA, WAKE ISLAND AND THE NORTHERN MARIANA ISLANDS), ANY STATE OF THE UNITED STATES OF AMERICA OR THE DISTRICT OF COLUMBIA (THE UNITED STATES) OR TO ANY U.S. PERSON (AS DEFINED IN REGULATION S OF THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE SECURITIES ACT)) OR IN OR INTO ANY JURISDICTION WHERE IT IS UNLAWFUL TO RELEASE, PUBLISH OR DISTRIBUTE THIS ANNOUNCEMENT (SEE “OFFER AND DISTRIBUTION RESTRICTIONS” BELOW). SES Financing S.à r.l., a wholly owned subsidiary of SES, announced the successful launch and pricing of the PNC5.25 Subordinated Perpetual with Automatic Conversion Events (“SPACE”) hybrid transaction, guaranteed on a subordinated basis by SES and SES Americom. SES Financing S.à r.l. is rated Ba1 (stable) and BBB- (stable) by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom